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EGFR-tyrosine kinase inhibitor (TKI) 
sensitivity of theses rare mutations differ 
from classic EGFR mutant. As a matter 
of fact, they are similar to EGFR wild-
type patients. Lohinai et al.’s2 results 
are in line with previous report. Rare 
EGFR mutations had a high incidence, 
almost the same as classic and synony-
mous (5%, 6%, and 4%; respectively). 
They were also associated with smok-
ing and poor response to EGFR-TKI as 
opposed to classic mutations. In addi-
tion, of the 49 rare mutations, 20 were 
never described before (not registered 
in the Catalogue of Somatic Mutations 
in Cancer [COSMIC] database).
We must be aware that the diag-
nostic of advanced non–small-cell lung 
cancer is often made by biopsy rather 
than resected specimen, and these rare 
mutations were all noted from samples 
of DNA extracted from formalin-fixed 
paraffin-embedded (FFPE) tissue. 
Artifacts can easily be observed when 
sequencing multiple polymerase chain 
reaction (PCR) amplification products 
of very small amounts of DNA, par-
ticularly if the DNA is isolated from 
paraffin-embedded tissue. Therefore, 
the hypothesis that several of these 
rare mutations might be actually 
PCR-amplification artifacts must be 
discussed.
Akbari et al.3 performed direct 
sequencing of the PCR-amplified cod-
ing region of the uracil-DNA glyco-
sylase gene using DNA isolated from 
FFPE tissue specimens from patients 
with gastric cancer (only one mutation 
in the uracil-DNA glycosylase gene 
in human cancer had been previously 
reported in a sporadic human glioblas-
toma). In nearly 35% of the samples, 
they detected base substitutions, which, 
after further investigation, proved to be 
PCR artifacts. They also demonstrated 
that very low concentration of DNA 
template in PCR mix can give rise to 
false base substitutions. Marchetti et 
al.4 identified 45 rare EGFR mutations 
in 70 samples of lung tumor DNA 
extracted from FFPE tissue, and they 
were all found to be artifacts. This was 
confirmed because they also found the 
same mutations in multiple amplifica-
tions of DNA extracted from FFPE of 
normal tissue (50 patients’ lymph nodes 
without neoplasm). In addition, series 
whose fresh-frozen tissue was used do 
not observed rare EGFR mutations.5
There are some hypotheses for 
the occurrence of artifactual mutations. 
For instance, base damages and large-
scale DNA fragmentation caused by the 
chemical preparation of FFPE samples 
might result in cytosine deamination. 
Thereby the taq DNA polymerase would 
insert an adenosine instead of a guano-
sine resulting in C → T and G → A tran-
sitions (so-called “a-rule”). Moreover, 
degraded PCR products allowed the taq 
DNA polymerase performs a “jump” 
from a damaged template to another to 
continue the extension.6
Some strategies were reported to 
prevent artifactual mutations. Routine 
application of microdissection and use 
of fresh-frozen tissue to enrich tumor-
cell DNA are one option. Also, if small 
amounts of DNA extract from FFPE 
were inevitable, addition of uracil-N- 
glycosylase to the DNA template before 
PCR amplification and the examina-
tion of multiple amplifications are 
imperative.
Because analysis of EGFR gene 
is mandatory for decision regarding 
EGFR-TKI use, the correct interpreta-
tion of EGFR exons 18 to 21 sequenc-
ing and its genetic alterations is crucial 
to select patients whom would benefit 
from treatment. Therefore, these data 
preclude the indiscriminate use of 
EGFR-TKI in patients harboring EGFR 
rare mutations and drive us to a more 
careful molecular analysis to identify 
molecular artifacts.
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In Response:
We thank Domingues et al. for 
their comment on our study and the 
opportunity to further discuss the 
clinical relevance of rare epidermal 
growth factor receptor (EGFR) muta-
tions, especially in an era where there 
is an urgent, unmet need to increase the 
number of lung cancer patients who can 
benefit from targeted therapies.
Their comment on the possibility 
that some of the rare mutations identi-
fied during the routine EGFR testing 
might be artifactual is well taken. While 
the demonstration of EGFR mutation is 
required to prescribe EGFR-TKI treat-
ment for lung adenocarcinoma patients, 
there are no definite requirements for 
the sample preparation, molecular diag-
nostic procedures or the type of EGFR 
mutations that needs to be identified. 
Our study was retrospective using the 
mutational data generated during the 
routine molecular pathological diagnosis 
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treatment in each patient with a rare 
EGFR mutation is of utmost impor-
tance to identify every patient who can 
benefit from this therapeutic modality.
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of formalin-fixed paraffin embedded 
tumor tissues or cytological samples, 
and the majority of cases were analyzed 
from bronchoscopic biopsy specimens, 
where the amount of DNA available for 
analysis was limited. Indeed, throughout 
the world, the overwhelming majority of 
EGFR molecular testing is performed on 
formalin-fixed surgical tumor specimens 
or biopsies, or even on cytological prep-
arations. We fully agree with Domingues 
et al. that the EGFR mutation analysis 
should be very carefully performed and 
interpreted, especially when rare or novel 
mutations are found. Therefore, we not 
only pointed out the possible clinical rel-
evance of rare EGFR mutations but also 
stated clearly in the interpretation of our 
results that our data needs to be validated 
in additional studies. However, it is now 
evident that certain rare mutations are 
sensitizing to anti-EGFR therapy and 
that these patients need to be identified 
and treated accordingly.1,2
It is important to discuss the pos-
sibility of formalin-fixation-related 
polymerase chain reaction artifacts 
in our study. First, the majority of the 
nonsynonymous rare EGFR mutations 
identified in our cohort have already 
been described in the COSMIC data-
base. Among the 20 previously not 
published rare EGFR mutations, there 
were three microdeletions and five 
point mutations which were not C->T 
or G->A transitions that often appear as 
formalin induced artifacts. Of note, five 
patients with novel rare EGFR mutations 
responded to therapy and had a survival 
benefit which would not be expected in 
the case of artifact mutations (i.e., in 
wild-type EGFR patients). Nevertheless, 
we hope that because an increasing 
number of EGFR  mutation analyses 
are being performed on non-formalin-
fixed specimens the spectra of validated 
somatic EGFR  mutations will eventually 
be established. Novel approaches—for 
instance using circulating tumor DNA in 
“liquid biopsy”—may overcome some 
of the limitations in the future.3
In summary, on the one hand, the 
harmonization of tissue processing and 
molecular pathological methods can 
further improve the reliability of EGFR 
mutational tests. On the other hand—as 
we concluded in our study—reporting 
the clinical response to EGFR-TKI 
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To the Editor:
The Chinese Thoracic Oncology 
Group has recently reported final over-
all survival (OS) results of a phase III 
study examining the effectiveness of 
